Latest Payments News

Atlas Pearls Ltd has declared a fully franked 1.4 cent per share dividend for the second half of FY25, lifting total dividends for the year to 2.4 cents, up from 1.85 cents in FY24.

Steadfast Group Limited has announced a fully franked ordinary dividend of AUD 0.117 per share for the half-year ending June 2025, accompanied by a Dividend Reinvestment Plan offering a 2.5% discount.

CTI Logistics Limited has announced a fully franked ordinary dividend of AUD 0.055 per share for the half-year ending June 2025, offering shareholders reinvestment and bonus security plans with attractive discounts.

CTI Logistics reported a modest revenue increase for FY2025 but faced a notable drop in net profit, maintaining steady dividends despite earnings pressure.

Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.

Global X Management (AUS) Limited has announced updated estimated distribution amounts for three of its ETFs listed on the ASX AQUA Market for the period ending 31 August 2025, alongside key dates for investors to note.

Betashares Capital Ltd has released estimated monthly distribution figures for 17 of its ETFs for the August 2025 period, setting key dates for investors ahead of final payouts.

Icetana Limited posted a $2.9 million net loss for FY2025, with revenues down 49% due to lower non-recurring sales, while recurring SaaS income grew. The company secured a $3.6 million strategic partnership with SoftBank Robotics, strengthening its foothold in Japan.

Ariadne Australia Limited reported a remarkable 409% jump in pre-tax profit for FY25, alongside a 38% revenue increase, yet faced a sharp decline in comprehensive income. The company declared a partially franked final dividend, signaling confidence amid mixed financial signals.

Entertainment Rewards Ltd reported a 12.7% increase in operating revenue for FY2025, driven by growth in key segments, but posted a wider net loss of $9.7 million amid higher expenses and a major convertible loan amendment.

Aeeris Ltd reported a 27.7% revenue increase to $4.36 million for FY25, driven by proprietary platform launches and expanded client contracts, while posting a net loss of $632,731. The company is poised for operational scale and cash flow positivity in FY26.

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.